How should I increase the dose of NovoLog Mix 70/30 (insulin aspart protamine/insulin aspart) for a patient taking 30 units in the morning and 30 units in the evening who has consistently high pre‑meal or fasting glucose (>180 mg/dL) despite diet and activity adherence?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Increasing NovoLog Mix 70/30 for Persistent Hyperglycemia

For a patient on NovoLog Mix 70/30 (30 units twice daily) with consistently high glucose (>180 mg/dL), you should immediately discontinue the premixed insulin and transition to a scheduled basal-bolus regimen, as premixed formulations are explicitly contraindicated for dose titration and carry unacceptable hypoglycemia risk.

Critical Problem with Current Regimen

  • NovoLog Mix 70/30 is explicitly contraindicated in hospitalized patients because randomized trials showed a 64% hypoglycemia rate versus 24% with basal-bolus therapy, leading to early trial termination. 1
  • The fixed 70:30 ratio cannot be adjusted independently, preventing you from addressing fasting versus post-prandial hyperglycemia separately and increasing hypoglycemia risk when meal intake varies. 2
  • Major diabetes guideline societies do not recommend premixed 70/30 insulin for initial therapy or dose titration due to safety concerns. 2
  • Premixed insulin requires consistent meal timing and carbohydrate intake, making it unsuitable for patients with variable eating patterns. 3, 1

Immediate Transition to Basal-Bolus Therapy

Calculate Total Daily Dose (TDD)

  • Current TDD = 60 units (30 units BID)
  • For severe hyperglycemia (glucose >180 mg/dL), you need 0.3–0.5 units/kg/day as your target TDD. 2

Split Into Basal and Prandial Components

  • Basal insulin (glargine or detemir): Give 50% of TDD = 30 units once daily at bedtime. 2, 4
  • Prandial insulin (lispro or aspart): Give 50% of TDD = 30 units total, divided as 10 units before each of the three main meals. 2, 4
  • Administer rapid-acting insulin 0–15 minutes before meals for optimal post-prandial control. 2

Systematic Titration Algorithm

Basal Insulin Titration

  • If fasting glucose 140–179 mg/dL: Increase basal dose by 2 units every 3 days. 2
  • If fasting glucose ≥180 mg/dL: Increase basal dose by 4 units every 3 days. 2
  • Target fasting glucose: 80–130 mg/dL. 2
  • Stop basal escalation when dose reaches 0.5–1.0 units/kg/day without achieving targets; add more prandial insulin instead. 2

Prandial Insulin Titration

  • Increase each meal dose by 1–2 units (≈10–15%) every 3 days based on 2-hour post-prandial glucose. 2, 4
  • Target post-prandial glucose: <180 mg/dL. 2, 4
  • If hypoglycemia occurs (<70 mg/dL), reduce the implicated dose by 10–20% immediately. 2

Correction Insulin Protocol

  • Add 2 units rapid-acting insulin for pre-meal glucose >250 mg/dL. 2
  • Add 4 units for pre-meal glucose >350 mg/dL. 2
  • Correction doses are in addition to scheduled prandial doses, never a replacement. 2

Monitoring Requirements

  • Daily fasting glucose to guide basal insulin adjustments. 2
  • Pre-meal glucose before each meal to calculate correction doses. 2
  • 2-hour post-prandial glucose after each meal to assess prandial adequacy. 2, 4
  • Bedtime glucose to evaluate overall daily pattern. 2
  • Reassess insulin doses every 3 days during active titration. 2

Foundation Therapy with Metformin

  • Continue metformin at maximum tolerated dose (up to 2,000–2,550 mg daily) when transitioning to basal-bolus insulin. 2
  • Metformin reduces total insulin requirements by 20–30% and provides superior glycemic control compared with insulin alone. 2
  • Never discontinue metformin when starting or intensifying insulin unless contraindicated. 2

Expected Clinical Outcomes

  • With properly implemented basal-bolus therapy, ≈68% of patients achieve mean glucose <140 mg/dL, compared with ≈38% using inadequate regimens like premixed insulin. 2
  • HbA1c reduction of 2–3% is achievable within 3–6 months with intensive titration. 2
  • Basal-bolus therapy does not increase hypoglycemia incidence when correctly applied versus premixed formulations. 2

Critical Pitfalls to Avoid

  • Never continue premixed insulin when dose titration is needed; the fixed ratio prevents independent adjustment of basal versus prandial coverage. 1, 2
  • Do not attempt to "increase" NovoLog Mix 70/30 by simply raising the total dose; this simultaneously increases both components in a fixed ratio, leading to either persistent hyperglycemia or hypoglycemia. 1, 2
  • Avoid relying on correction (sliding-scale) insulin alone without scheduled basal and prandial doses; this reactive approach is condemned by major diabetes guidelines. 2
  • Do not delay transition to basal-bolus therapy when glucose consistently exceeds 180 mg/dL on premixed insulin; prolonged hyperglycemia increases complication risk. 2

Alternative: Stepwise Prandial Addition (If Basal-Only First)

If you prefer a more gradual approach starting with basal insulin alone:

  • Start basal insulin (glargine) at 10 units once daily (or 0.1–0.2 units/kg). 2
  • Titrate basal insulin by 2–4 units every 3 days until fasting glucose reaches 80–130 mg/dL. 2
  • When basal insulin approaches 0.5 units/kg/day without achieving targets, add 4 units rapid-acting insulin before the largest meal. 2, 5
  • Add prandial insulin to additional meals sequentially as needed when post-meal glucose remains >180 mg/dL. 5

However, given your patient's persistent hyperglycemia (>180 mg/dL), immediate basal-bolus therapy is preferred over stepwise addition to achieve rapid control. 2, 4

References

Guideline

management of diabetes and hyperglycaemia in the hospital.

The Lancet Diabetes and Endocrinology, 2021

Guideline

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Insulin Aspart Dose Adjustment for Poorly Controlled Type 2 Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the optimal timing for the last dose of Novolog (insulin aspart protamine/insulin aspart) 70/30 when taking Lantus (insulin glargine)?
How should I convert a patient on 175 units daily of premixed 70/30 insulin (70 % NPH, 30 % regular) to a regimen with 60 % basal insulin and 40 % rapid‑acting insulin using high‑concentration insulin?
What is the difference between Isophane (NPH insulin) 40 and Human Mixtard (biphasic insulin) 30/70 in terms of glucose control?
Can I substitute Novolog (insulin aspart) 70/30 with a Novolog (insulin aspart) FlexPen in a patient with diabetes, particularly one with a history of insulin therapy?
What is the typical starting dose and administration schedule for Novolog (insulin aspart protamine/insulin aspart) 70/30 in patients requiring insulin therapy?
A patient taking Vyvanse (lisdexamfetamine) 30 mg each morning reports inability to sleep; what are the recommended management strategies?
Can you explain the mechanism of action of pembrolizumab (Keytruda), its recommended dosing schedule, alternative checkpoint inhibitor options, and monitoring for immune‑related adverse events?
What are the treatment options for a man with hypogonadism and erectile dysfunction who cannot receive testosterone replacement because of contraindications such as active prostate cancer, elevated hematocrit, need to preserve fertility, or severe untreated obstructive sleep apnea?
Do men have lifelong human papillomavirus (HPV) infection?
What is the significance of a urinalysis showing hematuria, proteinuria, bilirubinuria, and ketonuria, and what are the appropriate next steps?
Is olanzapine 5 mg more likely to cause emotional blunting than high‑dose aripiprazole?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.